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Background: Aldosterone receptor antagonists (ARA) classified as potassium sparing diuretics is administered concomitantly with loop diuretics 
for the management of patients with chronic heart failure (CHF) in usual clinical setting.Recently,ARA has been shown to decrease the morbidity and 
mortality in patients with systolic CHF and mild symptoms.However,there is no little information available on the efficacy of concomitant use of ARA 
and loop diuretics in CHF patients without and with mild symptoms.We sought to evaluate the effect of the concomitant use on the clinical outcome 
in CHF patients with NYHA 1 or 2 symptoms,in comparison to that of loop diuretics only.
Methods and Results: We prospectively studied 122 CHF outpatients (NYHA1/2:34/88) with loop diuretics,whose LV ejection fraction (LVEF) 
was less than 40% (29.7±7.2%) .At entry,72 patients had the administration of spironolactone. There were no significant differences in baseline 
clinical characteristics such as LVEF between patients with the concomitant use (CON) and loop diuretics with potassium supplement (Loop) 
.During a mean follow-up period 6.3±4.2 (0-15.4) years,32 of 122 patients had cardiac death (sudden death in 21 and pump failure death in 
11 patients) .Kaplan-Meier analysis revealed that cardiac death was significantly infrequently observed in patients with CON than those with 
Loop (24% vs 42%,p=0.02,hazard ratio 0.40,95% CI,0.18-0.99) .Notably,patients with CON had less sudden death than those with Loop (24% vs 
30%,p=0.02,hazard ratio 0.33,95% CI,0.12-0.91) ,while there was no significant difference in the incidence of pump failure death between them.
Conclusions: The concomitant use of spironolactone and loop diuretics would reduce the risk of sudden death in patients with NYHA class 1 or 2 CHF.
